Asadi Anar Mahsa, Foroughi Elaheh, Sohrabi Elika, Peiravi Samira, Tavakoli Yasaman, Kameli Khouzani Mozhgan, Behshood Parisa, Shamshiri Melika, Faridzadeh Arezoo, Keylani Kimia, Langari Seyedeh Faride, Ansari Akram, Khalaji Amirmohammad, Garousi Setareh, Mottahedi Mehran, Honari Sara, Deravi Niloofar
Student Research Committee, School of Medicine, Shahid Beheshti University of Medical Sciences, Tehran, Iran.
School of Medicine, Isfahan University of Medical Sciences, Isfahan, Iran.
Front Pharmacol. 2022 Nov 30;13:1036093. doi: 10.3389/fphar.2022.1036093. eCollection 2022.
The emerging COVID-19 pandemic led to a dramatic increase in global mortality and morbidity rates. As in most infections, fatal complications of coronavirus affliction are triggered by an untrammeled host inflammatory response. Cytokine storms created by high levels of interleukin and other cytokines elucidate the pathology of severe COVID-19. In this respect, repurposing drugs that are already available and might exhibit anti-inflammatory effects have received significant attention. With the and clinical investigation of several studies on the effect of antidepressants on COVID-19 prognosis, previous data suggest that selective serotonin reuptake inhibitors (SSRIs) might be the new hope for the early treatment of severely afflicted patients. SSRIs' low cost and availability make them potentially eligible for COVID-19 repurposing. This review summarizes current achievements and literature about the connection between SSRIs administration and COVID-19 prognosis.
新出现的新冠疫情导致全球死亡率和发病率急剧上升。与大多数感染一样，冠状病毒感染的致命并发症是由不受控制的宿主炎症反应引发的。高水平的白细胞介素和其他细胞因子引发的细胞因子风暴阐明了重症新冠的病理机制。在这方面，重新利用已有的、可能具有抗炎作用的药物受到了广泛关注。随着多项关于抗抑郁药对新冠预后影响的研究的开展和临床调查，先前的数据表明，选择性5-羟色胺再摄取抑制剂（SSRI）可能是重症患者早期治疗的新希望。SSRI成本低且容易获得，使其有可能适用于新冠治疗。这篇综述总结了目前关于使用SSRI与新冠预后之间联系的研究成果和文献。
